CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Bronx, NY
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This program will review current and emerging therapies for the management of moderate-to-severe uncontrolled asthma.
This activity will cover the treatment and management of patients with AML.
This case-based live activity will cover the treatment and management of patients with hemophilia A
This program will review current and emerging therapies for the management of HER2-positive gastric cancer.